Restoration of iron homeostasis and normal hepcidin levels appears to play a key role in freeing hemodialysis patients from having to receive erythropoiesis-stimulating agents.
Time-averaged hemoglobin levels, not hemoglobin cycling, is associated with an increased risk of left ventricular hypertrophy in pediatric dialysis patients, a study found.
Japanese post-marketing study identified no new safety concerns among patients with non-dialysis chronic kidney disease treated with darbepoetin alfa and followed up for 3 years.
In a Spanish study, endoscopic evaluation of patients with CKD and anemia revealed that 68.2% of patients had at least 1 gastrointestinal lesion.
New study "adds to the evidence of obesity-associated advantages," researchers conclude.
In a small study, intermittent vs continuous administration of IV iron resulted in less hemoglobin variability in hemodialysis patients with anemia.
Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
Patients with vs without anemia prior to starting hemodialysis (HD) were more likely to die despite achieving target hemoglobin levels at month 4 after HD initiation.
Anemia control may be one more reason to treat elevated parathyroid hormone levels.
Anemia is 66% and 84% more likely to develop among patients in the 3rd and 4th quartiles of serum fibroblast growth factor 23 level vs those in the 1st quartile.
Retacrit is biosimilar to the drugs Epogen and Procrit.
In a study, increases in red blood cell distribution width during the first year of dialysis was associated with greater risks for death.
Patients' mean hemoglobin levels stayed relatively stable after converting from an erythropoiesis-stimulating agent to the investigational drug.
New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.
Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.
In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.
Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.
The safety profile of CERA is similar for children as for adults.
To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.
Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.
Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)